As the European Central Bank’s recent rate cuts fuel optimism for further monetary easing, Sweden’s tech sector remains a focal point for investors seeking high growth opportunities amidst a broader positive market sentiment. In this dynamic environment, identifying stocks with strong fundamentals and innovative capabilities can be key to capitalizing on potential growth in the Swedish tech landscape.
Name
Revenue Growth
Earnings Growth
Growth Rating
Fortnox
20.12%
24.20%
★★★★★★
Hemnet Group
20.74%
26.12%
★★★★★★
Truecaller
20.45%
21.76%
★★★★★★
Xbrane Biopharma
53.90%
118.02%
★★★★★★
Scandion Oncology
40.71%
75.34%
★★★★★★
BioArctic
42.38%
98.40%
★★★★★★
Bonesupport Holding
33.76%
31.20%
★★★★★★
KebNi
32.82%
87.24%
★★★★★★
Yubico
20.52%
42.18%
★★★★★★
Skolon
32.37%
135.49%
★★★★★★
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Better Collective A/S is a digital sports media company operating in Europe, North America, and internationally with a market cap of SEK13.91 billion.
Operations: The company generates revenue primarily through its Publishing segment (€245.06 million) and Paid Media segment (€109.72 million).
Better Collective, a Swedish tech firm, has recently demonstrated robust financial growth with a notable increase in sales from EUR 78.12 million to EUR 99.12 million year-over-year as of June 2024. Despite this surge, the company’s net profit margins have dipped to 8% from last year’s 18.1%, reflecting some underlying challenges despite top-line growth. The firm is poised for future earnings expansion, projected at an impressive rate of 44.2% annually, outpacing the broader Swedish market’s expectation of 15.8%. This forecast aligns with Better Collective’s strategic initiatives presented at the SBC Summit and recent executive board enhancements aimed at bolstering governance and market position.
OM:BETCO Earnings and Revenue Growth as at Oct 2024
Simply Wall St Growth Rating: ★★★★★☆
Overview: BioInvent International AB (publ) is a clinical-stage company focused on discovering, researching, and developing novel immuno-modulatory antibodies for cancer treatment globally, with a market cap of approximately SEK2.85 billion.
Operations: BioInvent International generates revenue primarily through the development of antibody-based drugs, amounting to SEK52.67 million. The company is engaged in the clinical-stage research and development of novel immuno-modulatory antibodies aimed at cancer treatment across various international markets.
Story Continues